1. For Gilead, its coronavirus treatment is icing on the cake— FDA considering virtual advisory panels but delays GSK, Intercept meetings — Sanofi in COVID-19 mRNA vaccine deal with Translate Bio — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

BD vs. Bard

Discussion in 'Becton Dickinson' started by anonymous, Jun 13, 2019 at 12:20 AM.

  1. anonymous

    anonymous Guest

    So who’s calling the shots now? BD bought Bard yet Bard reps seem to look down on BD reps and Bard leadership is in place in many divisions. Does anyone else find the whole dynamic uncomfortable?
     
  2. anonymous

    anonymous Guest

    I know one thing, it was not a coincidence that the BD reps w access bag got shafted with territory alignments. You would be hard pressed to find many who even live within the geographical area they cover. Not to mention inheriting hospitals with declining business.
     
  3. anonymous

    anonymous Guest

    Care reps have it worse. Less pay and massive territories. Probably have better work life balance though.
     
  4. anonymous

    anonymous Guest

    Get ready for some serious double digit turnover in 2020 here especially the oncology division
     
  5. anonymous

    anonymous Guest

    Sounds like the endourology division in 2018/19. Mass exodus. They backfilled with associate tm's for 1/2 the price.
     
  6. anonymous

    anonymous Guest

    I second this. Place is going to hell right now. Everyone I talked to is beyond confused.